Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non …

A Nishiyama, N Katakami, H Yoshioka, M Iwasaku… - Lung Cancer, 2015 - Elsevier
Objective Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line
chemotherapy in patients with advanced non-squamous non-small-cell lung cancer …
被引用次数：16 相关文章

Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non …

A Nishiyama, N Katakami, H Yoshioka… - Lung Cancer …, 2015 - europepmc.org
Objective Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line
chemotherapy in patients with advanced non-squamous non-small-cell lung cancer …

Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non …

A Nishiyama, N Katakami, H Yoshioka, M Iwasaku… - Lung Cancer, 2015 - infona.pl
Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line
chemotherapy in patients with advanced non-squamous non-small-cell lung cancer …

Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non …

A Nishiyama, N Katakami, H Yoshioka… - Lung …, 2015 - lungcancerjournal.info
Objective Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line
chemotherapy in patients with advanced non-squamous non-small-cell lung cancer …

Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non …

A Nishiyama, N Katakami… - Lung cancer …, 2015 - pubmed.ncbi.nlm.nih.gov
Objective Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line
chemotherapy in patients with advanced non-squamous non-small-cell lung cancer …